Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

ACC 2025 Novel Drug Moving Forward for Lp(a) A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor for cardiovascular disease ...

Rybelsus (semaglutide) and Ozempic (semaglutide ... in adults with type 2 diabetes • to lower the risk of serious cardiovascular (heart and blood vessel) problems in adults with type 2 diabetes ...